/Charles%20River%20Laboratories%20International%20Inc_%20logo-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. Valued at $8.1 billion by market cap, the company offers animal research models in research and development for new drugs, devices, and therapies, serving pharmaceutical and biotechnology companies, hospitals, and academic institutions worldwide.
Shares of this pharmaceutical company have underperformed the broader market over the past year. CRL has declined marginally over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 11.7%. In 2026, CRL’s stock fell 17.7%, compared to the SPX’s marginal rise on a YTD basis.